EIDX - Eidos Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.39B
Enterprise Value 3
1.21B
Trailing P/E
N/A
Forward P/E 1
-15.25
PEG Ratio (5 yr expected) 1
-0.86
Price/Sales (ttm)
N/A
Price/Book (mrq)
10.15
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-24.65

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3265.02%
S&P500 52-Week Change 38.78%
52 Week High 349.72
52 Week Low 39.15
50-Day Moving Average 340.02
200-Day Moving Average 333.74

Share Statistics

Avg Vol (3 month) 3175.92k
Avg Vol (10 day) 3164.32k
Shares Outstanding 537.44M
Float 9.59M
% Held by Insiders 175.15%
% Held by Institutions 131.92%
Shares Short (Sep 30, 2019) 42.86M
Short Ratio (Sep 30, 2019) 416.37
Short % of Float (Sep 30, 2019) 425.92%
Short % of Shares Outstanding (Sep 30, 2019) 47.63%
Shares Short (prior month Aug 30, 2019) 43.24M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-19.25%
Return on Equity (ttm)-30.28%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -49.01M
Net Income Avi to Common (ttm)-46.25M
Diluted EPS (ttm)-1.27
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)131.4M
Total Cash Per Share (mrq)3.56
Total Debt (mrq)1.06M
Total Debt/Equity (mrq)0.80
Current Ratio (mrq)20.89
Book Value Per Share (mrq)3.58

Cash Flow Statement

Operating Cash Flow (ttm)-44.48M
Levered Free Cash Flow (ttm)-27.95M